Profil Institute extends cardiometabolic capabilities for diabetes, obesity clinical drug trials

Profil Institute for Clinical Research Cardiometabolic Research director Robert Schott said that assessing cardiac safety is a critical early objective for the evaluation of new drugs, particularly in compounds for the treatment of diabetes.

"At Profil Institute we are excited to be implementing new technologies and procedures which allow us to assess cardiac safety signals in Phase I drug research, specifically in our ability to detect a drug’s risk for causing sudden cardiac death with prolongation of the QT interval as a marker," Schott said.

"We understand that detection of cardiac safety signals is mission-critical in early drug development, and new technologies allow us to do this in a more cost-effective and timely manner for our customers."

Profil Institute CEO Marcus Hompesch said that when testing a new drug compound, they want a clinical research institute that can assess all possible adverse side-effects early, before the drug enters costly later phase clinical trials.

"In that respect, early phase clinical trials are certainly the most critical when determining whether or not a new drug will make it to market," Hompesch said.